a rapid clinical practice update in November 2023 that found insufficient evidence to support patients stopping the medications before endoscopic procedures."It is known that GLP-1 RAs significantly reduce the motility of the stomach and small bowel.
After propensity score matching for the 59 potential confounders, GLP-1 RA use had a higher incidence rate of aspiration pneumonia and was associated with a significantly higher risk for aspiration pneumonia, with a hazard ratio of 1.33.In a subgroup analysis based on endoscopy type, an elevated risk was observed among patients who underwent upper endoscopy and combined upper and lower endoscopy but not lower endoscopy .
At the same time, additional studies are needed to understand the optimal drug withholding windows before endoscopies and other procedures, they concluded. Wang, who wasn't involved with this study, co-authored the AGA rapid clinical practice update. He and colleagues advised continuing with a procedure as planned for patients on GLP-1 RAs who followed standard pre-procedure fasting instructions and didn't have nausea, vomiting, dyspepsia, or abdominal distention.may be considered, though it may not be possible in ambulatory or office-based endoscopy settings, Wang and colleagues wrote.
Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Pneumonia Aspiration Pneumonia Endoscopy Aspiration Sedation Sedative Sedative Use Stomach GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Receptors Virginia
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: ScienceDaily - 🏆 452. / 53 Read more »
Source: ScienceMagazine - 🏆 285. / 63 Read more »
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: WTVYNews4 - 🏆 590. / 51 Read more »